PCGF2 (MEL-18) as A Potential Drug Target (G7703)
PCGF2 (MEL-18) as A Potential Drug Target
Protein-coding genes (PCGs) have emerged as a promising drug target in recent years due to their potential to regulate various cellular processes. One of the protein encoded by the gene PCGF2 (MEL-18) has gained significant attention due to its potential involvement in various cellular processes, including cell adhesion, migration, and invasion. In this article, we will discuss PCGF2 (MEL-18) as a drug target and its potential implications in the development of new therapeutic approaches.
Structure and Function
PCGF2 (MEL-18) is a 21-kDa protein that is expressed in various tissues, including neural, epithelial, and muscle cells. The protein is composed of a unique N-terminal region that contains a putative transmembrane domain, a long N -terminal coiled-coil, and a C-terminal region that contains a putative G-protein-coupled receptor (GPCR) domain.
The N-terminal region of PCGF2 (MEL-18) contains a transmembrane domain that is known to play a crucial role in protein-protein interactions and the regulation of cellular processes. This region is rich in various putative transmembrane interactions (TMIs) that are involved in the regulation of cellular signaling pathways, including the TGF-β pathway.
The C-terminal region of PCGF2 (MEL-18) contains a GPCR domain that is known to play a crucial role in the regulation of cellular responses to various signaling pathways, including sensory and neurotransmitter signaling pathways. This region is composed of a single relative constant region (RC) and a variable region (VR) that contains multiple potential GPCR-interactive residues.
Expression and Localization
PCGF2 (MEL-18) is expressed in various tissues and cells, including neurons, endothelial cells, and muscle cells. It is predominantly expressed in the brain, where it is highly expressed in the hippocampus, prefrontal cortex, and other regions. PCGF2 ( MEL-18) is also expressed in various other tissues, including heart, lung, liver, and pancreas.
The protein is primarily localized to the cytoplasm of cells, where it is involved in various cellular processes, including cell adhesion, migration, and invasion. It is also involved in the regulation of cellular signaling pathways, including the TGF-β pathway.
Drug Targeting
PCGF2 (MEL-18) has been identified as a potential drug target due to its involvement in various cellular processes. The N-terminal region of PCGF2 (MEL-18) contains putative TMIs that are involved in the regulation of cellular signaling pathways, including the TGF-β pathway. Therefore, small molecules that can inhibit these interactions may be effective in drug targeting PCGF2 (MEL-18).
The C-terminal region of PCGF2 (MEL-18) contains a GPCR domain that is known to play a crucial role in the regulation of cellular responses to various signaling pathways, including sensory and neurotransmitter signaling pathways. Therefore, small molecules that can modulate the activity of this domain may also be effective in drug targeting PCGF2 (MEL-18).
Conclusion
In conclusion, PCGF2 (MEL-18) is a protein that has gained significant attention due to its potential involvement in various cellular processes. The N-terminal and C-terminal regions of PCGF2 (MEL-18) contain putative TMIs and GPCR domains, respectively, that are involved in the regulation of cellular signaling pathways. Therefore, small molecules that can inhibit these interactions may be effective in drug targeting PCGF2 (MEL-18). Further studies are needed to determine the full potential of PCGF2 (MEL-18 ) as a drug target and to develop new therapeutic approaches based on this protein.
Protein Name: Polycomb Group Ring Finger 2
Functions: Transcriptional repressor. Binds specifically to the DNA sequence 5'-GACTNGACT-3'. Has tumor suppressor activity. May play a role in control of cell proliferation and/or neural cell development. Regulates proliferation of early T progenitor cells by maintaining expression of HES1. Also plays a role in antero-posterior specification of the axial skeleton and negative regulation of the self-renewal activity of hematopoietic stem cells (By similarity). Component of a Polycomb group (PcG) multiprotein PRC1-like complex, a complex class required to maintain the transcriptionally repressive state of many genes, including Hox genes, throughout development. PcG PRC1 complex acts via chromatin remodeling and modification of histones; it mediates monoubiquitination of histone H2A 'Lys-119', rendering chromatin heritably changed in its expressibility (PubMed:26151332). Within the PRC1-like complex, regulates RNF2 ubiquitin ligase activity (PubMed:26151332)
More Common Targets
PCGF3 | PCGF3-AS1 | PCGF5 | PCGF6 | PCID2 | PCIF1 | PCK1 | PCK2 | PCLAF | PCLO | PCM1 | PCMT1 | PCMTD1 | PCMTD1-DT | PCMTD2 | PCNA | PCNA-AS1 | PCNAP1 | PCNAP3 | PCNP | PCNPP1 | PCNT | PCNX1 | PCNX2 | PCNX3 | PCNX4 | PCOLCE | PCOLCE-AS1 | PCOLCE2 | PCOTH | PCP2 | PCP4 | PCP4L1 | PCSK1 | PCSK1N | PCSK2 | PCSK4 | PCSK5 | PCSK6 | PCSK6-AS1 | PCSK7 | PCSK9 | PCTP | PCYOX1 | PCYOX1L | PCYT1A | PCYT1B | PCYT2 | PDAP1 | PDC | PDCD1 | PDCD10 | PDCD11 | PDCD1LG2 | PDCD2 | PDCD2L | PDCD4 | PDCD4-AS1 | PDCD5 | PDCD6 | PDCD6IP | PDCD6IPP2 | PDCD6P1 | PDCD7 | PDCL | PDCL2 | PDCL3 | PDCL3P4 | PDCL3P6 | PDE10A | PDE11A | PDE11A-AS1 | PDE12 | PDE1A | PDE1B | PDE1C | PDE2A | PDE2A-AS1 | PDE3A | PDE3B | PDE4A | PDE4B | PDE4C | PDE4D | PDE4DIP | PDE5A | PDE6A | PDE6B | PDE6C | PDE6D | PDE6G | PDE6H | PDE7A | PDE7B | PDE7B-AS1 | PDE8A | PDE8B | PDE9A | PDE9A-AS1 | PDF